Stem definition | Drug id | CAS RN |
---|---|---|
cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) receptors | 5091 | 706808-37-9 |
Molecule | Description |
---|---|
Synonyms:
|
Belatacept, a selective T-cell (lymphocyte) costimulation blocker, binds to CD80 and CD86 on antigen-presenting cells thereby blocking CD28 mediated costimulation of T lymphocytes. In vitro, belatacept inhibits T lymphocyte proliferation and the production of the cytokines interleukin-2, interferon-gamma, interleukin-4, and TNF-alfa. Activated T lymphocytes are the predominant mediators of immunologic rejection
|
Dose | Unit | Route |
---|---|---|
12.50 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
June 17, 2011 | EMA | ||
June 15, 2011 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Kidney transplant rejection | 207.47 | 40.22 | 42 | 1236 | 4076 | 46680708 |
Transplant rejection | 141.90 | 40.22 | 36 | 1242 | 9560 | 46675224 |
Graft loss | 101.23 | 40.22 | 16 | 1262 | 371 | 46684413 |
Cytomegalovirus infection | 69.78 | 40.22 | 24 | 1254 | 18120 | 46666664 |
Eye infection toxoplasmal | 61.16 | 40.22 | 10 | 1268 | 288 | 46684496 |
Tonsil cancer | 57.24 | 40.22 | 9 | 1269 | 201 | 46684583 |
Thrombotic microangiopathy | 56.68 | 40.22 | 17 | 1261 | 8289 | 46676495 |
Haemolytic uraemic syndrome | 55.27 | 40.22 | 13 | 1265 | 2501 | 46682283 |
Herpes simplex meningitis | 54.02 | 40.22 | 7 | 1271 | 35 | 46684749 |
Polyomavirus viraemia | 51.61 | 40.22 | 9 | 1269 | 384 | 46684400 |
Off label use | 49.52 | 40.22 | 56 | 1222 | 379785 | 46304999 |
Cytomegalovirus gastrointestinal infection | 47.50 | 40.22 | 8 | 1270 | 277 | 46684507 |
Pneumocystis jirovecii pneumonia | 42.85 | 40.22 | 16 | 1262 | 15232 | 46669552 |
Varicella zoster virus infection | 40.60 | 40.22 | 10 | 1268 | 2333 | 46682451 |
Disseminated cryptococcosis | 40.43 | 40.22 | 7 | 1271 | 286 | 46684498 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Kidney transplant rejection | 311.27 | 40.11 | 74 | 1590 | 7435 | 29943379 |
Transplant rejection | 109.55 | 40.11 | 34 | 1630 | 9172 | 29941642 |
Graft loss | 94.66 | 40.11 | 19 | 1645 | 851 | 29949963 |
Post transplant lymphoproliferative disorder | 73.31 | 40.11 | 22 | 1642 | 5284 | 29945530 |
COVID-19 | 66.71 | 40.11 | 28 | 1636 | 17850 | 29932964 |
BK virus infection | 59.87 | 40.11 | 18 | 1646 | 4346 | 29946468 |
Thrombotic microangiopathy | 51.54 | 40.11 | 19 | 1645 | 8591 | 29942223 |
Retinal artery occlusion | 46.39 | 40.11 | 12 | 1652 | 1672 | 29949142 |
Source | Code | Description |
---|---|---|
ATC | L04AA28 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D000082082 | Immune Checkpoint Inhibitors |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
FDA MoA | N0000182150 | CD80-directed Antibody Interactions |
FDA MoA | N0000182151 | CD86-directed Antibody Interactions |
FDA PE | N0000182829 | T Lymphocyte Costimulation Activity Blockade |
FDA EPC | N0000182830 | Selective T Cell Costimulation Blocker |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Renal transplant rejection | indication | 236570004 |
None
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
T-lymphocyte activation antigen CD80 | Surface antigen | INHIBITOR | DRUG LABEL | DRUG LABEL | |||||
T-lymphocyte activation antigen CD86 | Surface antigen | INHIBITOR | DRUG LABEL | DRUG LABEL |
ID | Source |
---|---|
E3B2GI648A | UNII |
D03222 | KEGG_DRUG |
4030905 | VANDF |
C1619962 | UMLSCUI |
CHEMBL1742990 | ChEMBL_ID |
DB06681 | DRUGBANK_ID |
D000069594 | MESH_DESCRIPTOR_UI |
8627 | INN_ID |
6892 | IUPHAR_LIGAND_ID |
1112973 | RXNORM |
183036 | MMSL |
27948 | MMSL |
d07787 | MMSL |
013827 | NDDF |
713475001 | SNOMEDCT_US |
714777004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
NULOJIX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0003-0371 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 250 mg | INTRAVENOUS | BLA | 30 sections |